{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:32:55Z","timestamp":1793151175360,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000853","name":"University of Glasgow","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014589","name":"Chief Scientist Office","doi-asserted-by":"publisher","award":["TCS\/21\/25"],"award-info":[{"award-number":["TCS\/21\/25"]}],"id":[{"id":"10.13039\/100014589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000589","name":"Chief Scientist Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010526","name":"NHS Greater Glasgow and Clyde","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010526","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018703","name":"CRUK Scotland Institute","doi-asserted-by":"publisher","award":["CTRQQR-2021\\\\100006"],"award-info":[{"award-number":["CTRQQR-2021\\\\100006"]}],"id":[{"id":"10.13039\/501100018703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["318434"],"award-info":[{"award-number":["318434"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["320463"],"award-info":[{"award-number":["320463"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jhepr.2026.101899","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:20:57Z","timestamp":1779290457000},"page":"101899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-6585","authenticated-orcid":false,"given":"Giulia","family":"Tesini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Greaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5624-3270","authenticated-orcid":false,"given":"Olivia","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Shand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-053X","authenticated-orcid":false,"given":"Angela","family":"Ammirabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"McHaffie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0271-0361","authenticated-orcid":false,"given":"Halima","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Meenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lampis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Chesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Casadei-Gardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-2786","authenticated-orcid":false,"given":"Timothy J.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Braconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jhepr.2026.101899_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101899_bib2","article-title":"Mapping the landscape of biliary tract cancer in Europe: challenges and controversies","volume":"50","author":"Rimassa","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"18","key":"10.1016\/j.jhepr.2026.101899_bib3","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101899_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101899_bib5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101899_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"16_suppl","key":"10.1016\/j.jhepr.2026.101899_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4093","article-title":"Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC)","volume":"42","author":"Finn","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10391","key":"10.1016\/j.jhepr.2026.101899_bib8","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101899_bib9","article-title":"Evolving precision: updates in targeted therapy for cholangiocarcinoma","author":"Tesini","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101899_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101899_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"clinicalguidelines@esmo.org EGCEa. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101899_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104540","article-title":"Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine)","volume":"10","author":"Malka","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhepr.2026.101899_bib13","volume":"35","author":"Ikeda","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jhepr.2026.101899_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4219","article-title":"A phase 1b\/2, safety lead-in and dose-expansion trial of ivosidenib plus durvalumab and gemcitabine\/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation","volume":"43","author":"Harding","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.jhepr.2026.101899_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS648","article-title":"HERIZON-BTC-302: a phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs. SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced\/metastatic biliary tract cancer (BTC)","volume":"43","author":"Harding","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101899_bib16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American pathologists, American society for clinical Pathology, and the American society of clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jhepr.2026.101899_bib17","volume":"43","author":"Harding","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101899_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101899_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221125096","article-title":"A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma","volume":"14","author":"Hempel","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101899_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101899_bib21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101899_bib22","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101899_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101899_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jhepr.2026.101899_bib25","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101899_bib26","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.1093\/oncolo\/oyae076","article-title":"EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance","volume":"29","author":"Kim","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.101899_bib27","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1005693","article-title":"Clinical significance of HER2 overexpression in biliary tract carcinoma --a meta analysis","volume":"15","author":"Xu","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2026.101899_bib28","volume":"9","author":"Kim","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"4_suppl","key":"10.1016\/j.jhepr.2026.101899_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.531","article-title":"Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"41","author":"Bouattour","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.jhepr.2026.101899_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.625","article-title":"Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"43","author":"Oh","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7813","key":"10.1016\/j.jhepr.2026.101899_bib31","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-020-2363-0","article-title":"Oncometabolites suppress DNA repair by disrupting local chromatin signalling","volume":"582","author":"Sulkowski","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101899_bib32","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1078-0432.CCR-17-2796","article-title":"IDH1\/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1\/2-mutant inhibitors","volume":"24","author":"Molenaar","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"375","key":"10.1016\/j.jhepr.2026.101899_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101899_bib34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1080\/07357907.2023.2242957","article-title":"Platinum sensitivity in IDH1\/2 mutated intrahepatic cholangiocarcinoma: not all \"BRCAness\" is created equal","volume":"41","author":"Doroshow","year":"2023","journal-title":"Cancer Invest"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101899_bib35","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/ijc.34182","article-title":"Platinum sensitivity in patients with IDH1\/2 mutated vs. wild-type intrahepatic cholangiocarcinoma: a propensity score-based study","volume":"151","author":"Niger","year":"2022","journal-title":"Int J Cancer"},{"issue":"16","key":"10.1016\/j.jhepr.2026.101899_bib36","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025635","article-title":"Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma: a large population-based study","volume":"100","author":"Liao","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"16_suppl","key":"10.1016\/j.jhepr.2026.101899_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e16192","article-title":"Extrahepatic cholangiocarcinoma versus intrahepatic cholangiocarcinoma: a comparison of survival outcomes and use of palliative care in diagnosed patients","volume":"40","author":"Nimish","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:41:42Z","timestamp":1793148102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926001709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589555926001709"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101899","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101899"}}